NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Aker Biomarine AS (OL: AKBM)

 
AKBM Technical Analysis
4
As on 22nd Nov 2024 AKBM STOCK Price closed @ 57.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 47.08 & Strong Buy for SHORT-TERM with Stoploss of 39.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

AKBMSTOCK Price

Open 52.70 Change Price %
High 57.20 1 Day 4.60 8.76
Low 52.70 1 Week 7.20 14.43
Close 57.10 1 Month 7.65 15.47
Volume 316758 1 Year 22.70 65.99
52 Week High 107.00 | 52 Week Low 31.40
 
OL Norway Most Active Stocks
EAM 0.17 6.25%
AOW 2.00 -5.21%
SHLF 10.20 -20.13%
ASA 0.08 0.00%
ENSU 0.83 -5.68%
NEL 2.96 1.37%
IDEX 0.13 0.00%
NHY 71.48 -0.50%
RECSI 4.29 6.98%
SATS 23.95 -3.62%
 
OL Norway Top Gainers Stocks
SOFF 40.00 21.21%
INSR 0.18 12.50%
TECO 0.22 10.00%
KOMP 5.22 9.66%
PHLY 64.40 9.15%
AKBM 57.10 8.76%
PLT 4.17 8.31%
PLT 4.17 8.31%
PLT 4.17 8.31%
CONTX 5.48 7.45%
 
OL Norway Top Losers Stocks
SHLF 10.20 -20.13%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
IOX 2.80 -12.77%
NODL 0.23 -11.54%
5PG 1.16 -9.38%
 
 
AKBM
Daily Charts
AKBM
Intraday Charts
Whats New @
Bazaartrend
AKBM
Free Analysis
 
AKBM Important Levels Intraday
RESISTANCE65.77
RESISTANCE62.99
RESISTANCE61.27
RESISTANCE59.55
SUPPORT54.65
SUPPORT52.93
SUPPORT51.21
SUPPORT48.43
 
AKBM Forecast November 2024
4th UP Forecast91.21
3rd UP Forecast80.27
2nd UP Forecast73.51
1st UP Forecast66.75
1st DOWN Forecast47.45
2nd DOWN Forecast40.69
3rd DOWN Forecast33.93
4th DOWN Forecast22.99
 
AKBM Weekly Forecast
4th UP Forecast62.01
3rd UP Forecast60.44
2nd UP Forecast59.46
1st UP Forecast58.49
1st DOWN Forecast55.71
2nd DOWN Forecast54.74
3rd DOWN Forecast53.76
4th DOWN Forecast52.19
 
AKBM Forecast2024
4th UP Forecast210.2
3rd UP Forecast161.1
2nd UP Forecast130.75
1st UP Forecast100.4
1st DOWN Forecast13.8
2nd DOWN Forecast-16.55
3rd DOWN Forecast-46.9
4th DOWN Forecast-96
 
 
AKBM Other Details
Segment EQ
Market Capital 3936995072.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
AKBM Address
AKBM
 
AKBM Latest News
 
Your Comments and Response on Aker Biomarine AS
 
AKBM Business Profile
Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates in two segments, Ingredients and Brands. The company provides krill oil products, including omega-3s, phospholipids, choline, and astaxanthin under the Superba, Kori, NKO, and K·REAL brands. It also offers Qrill aqua nutrient-rich feed ingredients for aquaculture; and QRILL pet, a functional ingredient for pet food. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste into products, such as shopping baskets and food trays. Aker BioMarine AS has an agreement with Medical Food Solutions Research to develop pharmaceutical therapies for brain and eye health based on Lysoveta. The company is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA. Address: Oksenøyveien 10, Lysaker, Norway, 1327
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service